Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2014 | Treatment of haematological malignancies with idelalisib

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Ian Flinn (Sarah Cannon Cancer Institute, Nashville, TN) discusses the selective oral inhibitor of phosphoinositide 3-kinase (PI3K) delta isoform (P110δ), idelalisib, in the management of hematological malignancies, including lymphoma and chronic lymphocytic leukemia (CLL). Idelalisib is considered in combination with other therapies to enhance efficacy endpoints.